Data mining reveals complex interactions of risk factors and clinical feature profiling associated with the staging of non-hepatitis B virus/non-hepatitis C virus-related hepatocellular carcinoma

Hepatology Research

Volumn 41, Issue 6, 2011, Pages 564-571

  Kawaguchi, Takumi ^a   Kakuma, Tatsuyuki ^a   Yatsuhashi, Hiroshi ^b   Watanabe, Hiroshi ^c   Saitsu, Hideki ^d   Nakao, Kazuhiko ^e   Taketomi, Akinobu ^f   Ohta, Satoshi ^g   Tabaru, Akinari ^h   Takenaka, Kenji ⁱ   Mizuta, Toshihiko ^j   Nagata, Kenji ^k   Komorizono, Yasuji ^l   Fukuizumi, Kunitaka ^d   Seike, Masataka ^m   Matsumoto, Shuichi ⁿ   Maeshiro, Tatsuji ^o   Tsubouchi, Hirohito ^p   Muro, Toyokichi ^q   Inoue, Osami ^r   Akahoshi, Motoo ^s   Sata, Michio ^a   more..

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^c FUKUOKA RED CROSS HOSPITAL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^e NAGASAKI UNIVERSITY   (Japan)

^f KYUSHU UNIVERSITY   (Japan)

^g NATIONAL KYUSHU CANCER CENTER   (Japan)

^h UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

ⁱ Fukuoka City Hospital   (Japan)

^j SAGA UNIVERSITY   (Japan)

^k UNIVERSITY OF MIYAZAKI   (Japan)

^l Nanpuh Hospital   (Japan)

^m OITA UNIVERSITY   (Japan)

ⁿ Fukuoka Tokushukai Medical Center   (Japan)

^o UNIVERSITY OF THE RYUKYUS   (Japan)

^p KAGOSHIMA UNIVERSITY   (Japan)

^q National Hospital Organization   (Japan)

^r Nagasaki Labour Welfare Hospital   (Japan)

^s Nishinihon Hospital   (Japan)

more..

Author keywords

Data mining; Disease progression; Hepatoma; Non viral hepatitis; Tumor marker

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; DECARBOXYPROTHROMBIN;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALGORITHM; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER STAGING; CLINICAL FEATURE; DATA BASE; DATA MINING; DECISION TREE; DISEASE CLASSIFICATION; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; NON HEPATITIS B VIRUS NON HEPATITIS C VIRUS RELATED HEPATOCELLULAR CARCINOMA; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS;

EID: 79957571513     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00799.x     Document Type: Article

References (51)

1. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134: 1752-63.
2. Kawaguchi T, Taniguchi E, Itou M, Sumie S, Yamagishi SI, Sata M. The pathogenesis, complications and therapeutic strategy for hepatitis C virus-associated insulin resistance in the era of anti-viral treatment. Rev Recent Clin Trials 2010; 5: 147-57.
3. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-32.
4. Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology 2010; 53: 39-43.
5. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010; 42 (Suppl 3): S206-14.
6. Nouso K, Kobayashi Y, Nakamura S etal. Evolution of prognostic factors in hepatocellular carcinoma in Japan. Aliment Pharmacol Ther 2010; 31: 407-14.
7. Tanaka H, Imai Y, Hiramatsu N etal. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. Ann Intern Med 2008; 148: 820-6.
8. Taura N, Fukushima N, Yatsuhashi H etal. The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area. Med Sci Monit 2010; 17: PH7-11.
9. Abe H, Yoshizawa K, Kitahara T, Aizawa R, Matsuoka M, Aizawa Y. Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo. J Gastroenterol 2008; 43: 967-74.
10. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-50.
11. Hassan MM, Hwang LY, Hatten CJ etal. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36: 1206-13.
12. Kiyosawa K, Umemura T, Ichijo T etal. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004; 127: S17-26.
13. Bellazzi R, Zupan B. Predictive data mining in clinical medicine: current issues and guidelines. Int J Med Inform 2008; 77: 81-97.
14. Kalisch M, Fellinghauer BA, Grill E etal. Understanding human functioning using graphical models. BMC Med Res Methodol 2010; 10: 14-23.
15. Edwards D. Introduction to Graphical Modelling. New York: Springer-Verlag, 2000.
16. Pielou EC. The Interpretation of Ecological Data. A Primer on Classification and Ordination, 1st edn. New York: John Wiley&Sons, Inc., 1984.
17. Legendre P, Legendre L. Numerical Ecology, 2nd edn. Amsterdam: Elsevier Science, 1998.
18. Tsai CL, Camargo CA Jr. Methodological considerations, such as directed acyclic graphs, for studying "acute on chronic" disease epidemiology: chronic obstructive pulmonary disease example. J Clin Epidemiol 2009; 62: 982-90.
19. Kurosaki M, Matsunaga K, Hirayama I etal. A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol Res 2010; 40: 251-60.
20. Kurosaki M, Sakamoto N, Iwasaki M etal. Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. J Gastroenterol 2010 (in press).
21. Pauker SG, Kassirer JP. The threshold approach to clinical decision making. N Engl J Med 1980; 302: 1109-17.
22. Lee A, Joynt GM, Ho AM, Keitz S, McGinn T, Wyer PC. Tips for teachers of evidence-based medicine: making sense of decision analysis using a decision tree. J Gen Intern Med 2009; 24: 642-8.
23. Guo J, Wang W, Liao P etal. Identification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis. Cancer Sci 2009; 100: 2292-301.
24. Warwick J, Vardaki E, Fattizzi N etal. Defining the surgical management of suspected early-stage ovarian cancer by estimating patient numbers through alternative management strategies. BJOG 2009; 116: 1225-41.
25. Kudo M, Okanoue T. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007; 72 (Suppl 1): 2-15.
26. Mazzaferro V, Regalia E, Doci R etal. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
27. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
28. Sanz-Cameno P, Trapero-Marugan M, Chaparro M, Jones EA, Moreno-Otero R. Angiogenesis: from chronic liver inflammation to hepatocellular carcinoma. J Oncol 2010; article no.: 272170.
29. Inagaki Y, Tang W, Xu H etal. Des-gamma-carboxyprothrombin: clinical effectiveness and biochemical importance. Biosci Trends 2008; 2: 53-60.
30. Wang XW, Xie H. Alpha-fetoprotein enhances the proliferation of human hepatoma cells in vitro. Life Sci 1999; 64: 17-23.
31. Weitz IC, Liebman HA. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology 1993; 18: 990-7.
32. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002; 62 (Suppl 1): 57-63.
33. Marrero JA, Lok AS. Newer markers for hepatocellular carcinoma. Gastroenterology 2004; 127: S113-19.
34. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007; 37 (Suppl 2): S88-94.
35. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-8.
36. Kawaguchi T, Sata M. Importance of hepatitis C virus-associated insulin resistance: therapeutic strategies for insulin sensitization. World J Gastroenterol 2010; 16: 1943-52.
37. Kawaguchi T, Taniguchi E, Morita Y etal. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. Liver Int 2010; 30: 479-86.
38. Tazawa J, Maeda M, Nakagawa M etal. Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C. Dig Dis Sci 2002; 47: 710-15.
39. Brandon-Warner E, Sugg JA, Schrum LW, McKillop IH. Silibinin inhibits ethanol metabolism and ethanol-dependent cell proliferation in an in vitro model of hepatocellular carcinoma. Cancer Lett 2010; 291: 120-9.
40. Chang YJ, Chiu CC, Wu CH etal. Glucose-regulated protein 78 (GRP78) silencing enhances cell migration but does not influence cell proliferation in hepatocellular carcinoma. Ann Surg Oncol 2010; 17: 1703-9.
41. Flanders KC. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 2004; 85: 47-64.
42. Gyamfi MA, Wan YJ. Pathogenesis of alcoholic liver disease: the role of nuclear receptors. Exp Biol Med (Maywood) 2010; 235: 547-60.
43. Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 2010; 316: 1324-31.
44. Xing F, Saidou J, Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci 2010; 15: 166-79.
45. Hamamura K, Shiratori Y, Shiina S etal. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein. Cancer 2000; 88: 1557-64.
46. Miyaaki H, Nakashima O, Kurogi M, Eguchi K, Kojiro M. Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J Gastroenterol 2007; 42: 962-8.
47. Toyoda H, Kumada T, Kiriyama S etal. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006; 4: 111-17.
48. Ong J, Younossi ZM, Reddy V etal. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001; 7: 797-801.
49. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-8.
50. Hashimoto E, Yatsuji S, Kaneda H etal. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res 2005; 33: 72-6.
51. Ohki T, Tateishi R, Shiina S etal. Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH. Gut 2009; 58: 839-44.